Important Notice, Table of Contents, and Definitions [Important Notice](index=2&type=section&id=Important%20Notice) The board and senior management guarantee report accuracy, advise on investment risks, and confirm no cash dividends or bonus shares for the period - The company's board of directors and senior management commit to the truthfulness, accuracy, and completeness of the report content, advising investors to pay attention to the risks and countermeasures in Section III 'Management Discussion and Analysis'[4](index=4&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital during the reporting period[5](index=5&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section lists the detailed table of contents, including company profile, management discussion and analysis, corporate governance, significant matters, share changes, bond information, financial reports, and other submitted data - The report's main sections include company profile and key financial indicators, management discussion and analysis, corporate governance, environment and society, significant matters, share changes and shareholder information, bond-related information, financial report, and a catalog of reference documents[7](index=7&type=chunk)[8](index=8&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section provides definitions for common terms used in the report, covering company and subsidiary names, financial and investment terms, and biological and pharmaceutical professional terms to ensure clear understanding - The report defines abbreviations for the company and its subsidiaries, such as "Sichuan Shuangma", "Shuangma Yibin", and "Shenzhen Jianyuan"[10](index=10&type=chunk) - It explains professional terms in finance and investment, such as IPO (Initial Public Offering), VC (Venture Capital), and PE (Private Equity)[10](index=10&type=chunk) - Key concepts in the biopharmaceutical field are detailed, including ADC (Antibody-Drug Conjugate), peptides, GLP-1 (Glucagon-Like Peptide-1), CDMO (Contract Development and Manufacturing Organization), DMF filing (Drug Master File), and GMP/cGMP (Good Manufacturing Practice/current Good Manufacturing Practice)[10](index=10&type=chunk)[12](index=12&type=chunk) Company Profile and Key Financial Indicators [Company Profile](index=8&type=section&id=Company%20Profile) Sichuan Harmony Shuangma Co, Ltd, stock ticker "Sichuan Shuangma" and stock code 000935, is listed on the Shenzhen Stock Exchange, with Xie Jianping as its legal representative - The company's stock abbreviation is "Sichuan Shuangma", stock code 000935, listed on the Shenzhen Stock Exchange[15](index=15&type=chunk) - The company's legal representative is Xie Jianping[15](index=15&type=chunk) [Contact Person and Information](index=8&type=section&id=Contact%20Person%20and%20Information) The company's Board Secretary is Huang Canwen, Securities Affairs Representative is Jing Jing, with contact address in Chengdu, Sichuan, and provided phone, fax, and email - The Board Secretary is Huang Canwen, and the Securities Affairs Representative is Jing Jing[16](index=16&type=chunk) - The company's contact address is 26th Floor, Office Building 1, Chengdu International Finance Square, No 1, Section 3, Hongxing Road, Jinjiang District, Chengdu, Sichuan Province[16](index=16&type=chunk) - The investor inquiry hotline is 028-63231548, and the email address is public.sm@sc-shuangma.com[16](index=16&type=chunk) [Other Information](index=8&type=section&id=Other%20Information) During the reporting period, there were no changes to the company's registered address, office address, website, email, or information disclosure and archiving locations, with specific details available in the 2024 annual report - The company's contact information, information disclosure, and archiving locations remained unchanged during the reporting period, with specific details available in the 2024 annual report[17](index=17&type=chunk)[18](index=18&type=chunk) [Key Accounting Data and Financial Indicators](index=9&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) During this reporting period, the company's operating revenue increased by 30.42% year-on-year, net profit attributable to shareholders increased by 13.42%, and net profit excluding non-recurring gains and losses increased by 70.14%, with total assets and net assets attributable to shareholders also growing Key Accounting Data and Financial Indicators (Current Reporting Period vs. Same Period Last Year) | Indicator | Current Reporting Period (RMB) | Same Period Last Year (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 629,197,790.08 | 482,425,424.71 | 30.42% | | Net Profit Attributable to Shareholders of Listed Company | 128,592,907.80 | 113,380,825.19 | 13.42% | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-recurring Gains and Losses | 161,776,715.50 | 95,083,548.35 | 70.14% | | Net Cash Flow from Operating Activities | 156,155,024.91 | 163,422,457.83 | -4.45% | | Basic Earnings Per Share (RMB/share) | 0.17 | 0.15 | 13.33% | | Diluted Earnings Per Share (RMB/share) | 0.17 | 0.15 | 13.33% | | Weighted Average Return on Net Assets | 1.71% | 1.53% | Increased by 0.18 percentage points | | **Period-End Indicators** | **Current Period-End (RMB)** | **Previous Year-End (RMB)** | **Change from Previous Year-End** | | Total Assets | 9,092,603,391.24 | 8,991,376,516.63 | 1.13% | | Net Assets Attributable to Shareholders of Listed Company | 7,603,913,228.64 | 7,475,317,745.70 | 1.72% | [Differences in Accounting Data under Domestic and Overseas Accounting Standards](index=9&type=section&id=Differences%20in%20Accounting%20Data%20under%20Domestic%20and%20Overseas%20Accounting%20Standards) During the reporting period, the company had no differences in net profit and net assets between financial reports disclosed under International Accounting Standards or overseas accounting standards and Chinese Accounting Standards - The company had no differences in net profit and net assets under domestic and overseas accounting standards during the reporting period[21](index=21&type=chunk)[22](index=22&type=chunk) [Non-Recurring Gains and Losses and Amounts](index=9&type=section&id=Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) The total non-recurring gains and losses for this reporting period amounted to RMB -33,183,807.70, primarily due to the one-time impact of estimated limestone mining rights fees, combined with government subsidies and structured deposit income Non-Recurring Gains and Losses and Amounts | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains and losses from disposal of non-current assets | 6,388.04 | | | Government subsidies included in current profit and loss | 6,650,576.04 | Mainly due to subsidiaries receiving VAT refunds for comprehensive resource utilization and government support funds | | Gains and losses from entrusted investments or asset management | 206,035.80 | Structured deposit income | | One-time impact on current profit and loss due to adjustments in tax, accounting, and other laws and regulations | -45,895,612.00 | Estimated limestone mining rights fees for the period from July 1, 2017, to December 31, 2024, already consumed | | Other non-operating income and expenses apart from the above | 72,000.40 | | | Less: Income tax impact | -5,933,928.57 | | | Impact on minority interests (after tax) | 157,124.55 | | | Total | -33,183,807.70 | | Management Discussion and Analysis [Company's Main Businesses During the Reporting Period](index=11&type=section&id=Company%27s%20Main%20Businesses%20During%20the%20Reporting%20Period) The company primarily engages in industrial investment and management and private equity fund management, with core assets including building materials manufacturing, biopharmaceutical R&D and production, and private equity fund management companies; during the reporting period, the company's building materials business faced market challenges, biopharmaceutical business benefited from GLP-1 drug market expansion, and private equity investment business developed steadily under policy support - The company's main businesses cover building materials manufacturing, biopharmaceutical R&D and production, and private equity fund management[27](index=27&type=chunk) - The company's strategic positioning focuses on new industrialization, artificial intelligence, and biotechnology, aligning with national scientific and technological innovation to lead a modern industrial system, targeting new technologies, models, and consumption[31](index=31&type=chunk) [Company Introduction](index=11&type=section&id=Company%20Introduction) Sichuan Shuangma, established in 1998 and listed in 1999, primarily manages building materials, biopharmaceuticals, and private equity funds, with its building materials business in Yibin benefiting from regional infrastructure, its biopharmaceutical business centered on Shenzhen Jianyuan focusing on peptide R&D and production with global supply capabilities, and its private equity fund management business, Xizang Jinhe, managing nearly RMB 28 billion across diverse investment sectors - The company's building materials manufacturing business produces cement, commercial clinker, and aggregates, with annual capacities of 2 million tons and 5 million tons respectively, benefiting from infrastructure projects in Yibin City[28](index=28&type=chunk) - The company's biopharmaceutical business, centered on Shenzhen Jianyuan, specializes in peptide product R&D and production, covering peptide APIs, CDMO, and cosmetic peptides, with core APIs registered in multiple countries and global supply capabilities[29](index

Market Overview - On August 27, the diversified financial sector declined by 0.75% compared to the previous trading day, with Sichuan Shuangma leading the decline [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable gainers included: - Zhongyou Capital (000617) with a closing price of 12.38, up 4.47% and a trading volume of 6.0894 million shares, totaling 7.561 billion yuan [1] - *ST Rendo (002647) closed at 5.82, up 1.39% with a trading volume of 248,400 shares, totaling 146 million yuan [1] - Major decliners included: - Sichuan Shuangma (000935) closed at 20.00, down 6.89% with a trading volume of 242,800 shares, totaling 501 million yuan [2] - Hongming (001236) closed at 12.53, down 4.79% with a trading volume of 311,400 shares, totaling 402 million yuan [2] Capital Flow - The diversified financial sector experienced a net outflow of 685 million yuan from institutional investors, while retail investors saw a net inflow of 762 million yuan [2] - The capital flow for key stocks showed: - Zhongyou Capital had a net inflow of 287.1 million yuan from institutional investors, while retail investors had a net outflow of 136 million yuan [3] - New Power Financial (600318) saw a net inflow of 77.59 million yuan from institutional investors, with retail investors experiencing a net outflow of 42.75 million yuan [3]

中国经济网北京8月27日讯 四川双马（000935）（000935.SZ）昨日晚间披露《关于持股5%以上股东减持股份的预 披露公告》。 根据公告，股东LAFARGE CHINA OFFSHORE HOLDING COMPANY（LCOHC）LTD.（以下简称"LCOHC"）计 划在公告披露之日起15个交易日后的连续90个自然日内以集中竞价和大宗交易方式合计减持公司股份不超过 7,572,200股（含本数），占公司总股本的0.9919%，占剔除公司回购专用证券账户中的股份数量后总股本的 1.0000%。其中，以集中竞价方式减持公司股份不超过3,786,100股（含本数），占剔除公司回购专用证券账户中的 股份数量后总股本的0.5000%，以大宗交易方式减持公司股份不超过3,786,100股（含本数），占剔除公司回购专用 证券账户中的股份数量后总股本的0.5000%。 股东天津赛克环企业管理中心（有限合伙）（以下简称"天津赛克环"）计划在公告披露之日起15个交易日后的连 续90个自然日内以集中竞价和大宗交易方式合计减持公司股份不超过7,572,200股（含本数），占公司总股本的 0.9919%，占剔除公司回购专用证 ...

格隆汇8月27日｜四川双马(000935.SZ)现跌4.93%报20.42元，暂成交4亿元，最新市值155.9亿元。四川 双马公告称，公司股东LCOHC和天津赛克环企业管理中心(有限合伙)分别计划在本公告披露之日起15 个交易日后的连续90个自然日内以集中竞价和大宗交易方式合计减持本公司股份不超过757.22万股，占 公司总股本的0.9919%，占剔除回购专用证券账户中的股份数量后总股本的1%。(格隆汇) ...

Company Summary - Sichuan Shuangma announced that LAFARGE CHINA OFFSHORE HOLDING COMPANY LTD plans to reduce its stake by up to approximately 7.57 million shares, accounting for 0.9919% of the total share capital [1] - Tianjin Saikehuan Enterprise Management Center also plans to reduce its stake by up to approximately 7.57 million shares, representing 0.9919% of the total share capital [1] - As of the announcement, Sichuan Shuangma's revenue composition for 2024 is as follows: cement manufacturing accounts for 55.28%, private equity investment management accounts for 42.07%, and biopharmaceuticals account for 2.65% [1] Market Overview - The market capitalization of Sichuan Shuangma is currently 16.4 billion yuan [2]

Core Viewpoint - On August 26, no A-share listed companies disclosed any increase in shareholding, while 14 companies announced share reductions, indicating a trend of shareholder divestment in the market [1]. Summary by Category Share Reduction Details - Dabo Medical: Shareholder Dabo International plans to reduce its stake by no more than 2% [2] - Sichuan Shuangma: Shareholders plan to collectively reduce their stake by no more than 2% [2] - Gaolan Co.: No specific details provided [2] - Yingpais: Specific shareholder Qingdao Qingying intends to reduce no more than 200,000 shares [2] - Chaoyang Technology: Shareholders plan to reduce no more than 3% of their shares [2] - Shenke Da: Director and Deputy General Manager Zhang Xinming plans to reduce no more than 0.88% of shares [2] - Xindong Link: Electronic Institute and Microelectronics Institute plan to collectively reduce no more than 1% of shares [2] - Guomai Culture: Some directors and senior management plan to reduce no more than 0.05% of shares [2] - Zhongwei Company: Xuexin Investment plans to reduce no more than 2% of the total share capital [2] - Shenma Power: Chen Xiaoqin plans to reduce no more than 3% of shares [2] - Hongxun Technology: Some directors and senior management plan to reduce their shares [2] - Weiming Environmental Protection: Major shareholders and concerted actors plan to reduce no more than 1.55% of shares [2] - Yicheng Material: Guoxin Shanghai plans to reduce no more than 1.46% of the total share capital [2] - Liande Co.: Shareholders plan to collectively reduce no more than 2.37% of shares [2]

证券代码：000935 证券简称：四川双马 公告编号：2025-40 四川和谐双马股份有限公司 关于持股5%以上股东减持股份的预披露公告 公司持股 5%以上股东 LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD.、 天津赛克环企业管理中心（有限合伙）保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 1、持有四川和谐双马股份有限公司（简称"本公司"）股份 133,952,761 股（占本公司总股本比例 17.5459%）的股东 LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD.（简称"LCOHC"）计划在本公告披露之日起 15 个交易日 后的连续 90 个自然日内以集中竞价和大宗交易方式合计减持本公司股份不超过 7,572,200 股（含本数），占本公司总股本的 0.9919%，占剔除本公司回购专用证 券账户中的股份数量后总股本的 ...

四川和谐双马股份有限公司 公司持股 5%以上股东 LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD.、 天津赛克环企业管理中心（有限合伙）保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 证券代码：000935 证券简称：四川双马 公告编号：2025-40 二、本次减持计划的主要内容 （一）LCOHC 拟减持的具体安排 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 股（占本公司总股本比例 17.5459%）的股东 LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD.（简称"LCOHC"）计划在本公告披露之日起 15 个交易日 后的连续 90 个自然日内以集中竞价和大宗交易方式合计减持本公司股份不超过 券账户中的股份数量后总股本的 1.0000%。 天津赛克环企业管理中心（有限合伙） （简称"天津赛克环"）计划在本公告披露 之日起 15 个交易日后的连续 90 个自然日内以集中 ...

每经AI快讯，8月26日，四川双马(000935.SZ)公告称，公司股东LCOHC和天津赛克环企业管理中心 （有限合伙）分别计划在本公告披露之日起15个交易日后的连续90个自然日内以集中竞价和大宗交易方 式合计减持本公司股份不超过757.22万股，占公司总股本的0.9919%，占剔除回购专用证券账户中的股 份数量后总股本的1.0000%。减持原因为股东自身资金需求。减持计划实施期间内，若公司发生送股、 资本公积金转增股本等股份变动事项，则减持数量进行相应调整。减持价格将按照减持时的市场价格和 交易方式确定。 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 蒙方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-08-20 | 000935 | 四川双马 | 18.39 | 10.90 | 200.45 机构专用 | | 中信建投证券股份 | | | | | | | | | 有限公司北京东城 | | | | | | | | | 分公司 | | 2025-08-20 | 000935 | 四川双马 | 18.39 | 10.90 | 200.45 机构专用 | | 中信建投证券股份 | | | | | | | | | 有限公司北京东城 | | | | | | | | | 分公司 | | 2025-08-20 | 000935 | 四川双马 | 18.39 | 10.90 | 200.45 机构专用 | | 中信建投证券股份 | | | | | | | | | 有限公司北京东城 | | | | | | | | | 分公司 | ...